WO2019124267A1 - Procédé de test pour le diagnostic de la maladie de niemann-pick type c - Google Patents

Procédé de test pour le diagnostic de la maladie de niemann-pick type c Download PDF

Info

Publication number
WO2019124267A1
WO2019124267A1 PCT/JP2018/046159 JP2018046159W WO2019124267A1 WO 2019124267 A1 WO2019124267 A1 WO 2019124267A1 JP 2018046159 W JP2018046159 W JP 2018046159W WO 2019124267 A1 WO2019124267 A1 WO 2019124267A1
Authority
WO
WIPO (PCT)
Prior art keywords
biomarker
amount
niemann
test method
pick disease
Prior art date
Application number
PCT/JP2018/046159
Other languages
English (en)
Japanese (ja)
Inventor
隆一 真嶋
Original Assignee
国立研究開発法人国立成育医療研究センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立研究開発法人国立成育医療研究センター filed Critical 国立研究開発法人国立成育医療研究センター
Publication of WO2019124267A1 publication Critical patent/WO2019124267A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Definitions

  • the present invention relates to an inspection method and the like for diagnosis of Niemann-Pick disease type C.
  • NPC Niemann-Pick disease type C
  • NPC1 OMIM 607623
  • NPC2 OMIM 601015) gene
  • Such lipids include oxysterols such as cholestane-3 ⁇ , 5 ⁇ , 6 ⁇ -triol and 7-ketocholesterol (Non-patent documents 4 to 9), bile acids (Non-patent documents 10 to 14), and glycosylated cholesterol ( Various cholesterol metabolites such as Non-Patent Document 15) can be mentioned.
  • the NPC1 protein is a membrane protein within the lysosome and facilitates transport of cholesterol from the lysosome to the plasma membrane.
  • NPC2 is a soluble protein in lysosomes and binds stoichiometrically with cholesterol.
  • Non-patent Document 2 Based on these biochemical properties of NPC1 and NPC2, the mechanism of NPC is believed to be due, at least in part, to a defect in proper lipid migration in cells (Non-patent Document 2). This possibility has been demonstrated in several established murine NPC models as treatment with cyclodextrin (a cyclic oligosaccharide that promotes cholesterol transport across the plasma membrane) has shown positive therapeutic results. (Non-Patent Documents 16 to 18). In recent years, 380 or more pathogenic mutations have been registered in the database (Non-patent Document 19). Moreover, in recent years, the morbidity rate of classical NPC has been shown to be about 1 / 10,000, but the incidence rate of late-onset NPC is not sufficiently predicted (Non-Patent Document 19) ).
  • Non-patent documents 2 to 3 biosynthesis of sphingomyelin originates from serine and palmitoyl CoA in the endoplasmic reticulum and is subjected to an enzymatic reaction by serine: palmitoyl CoA transferase (EC 2.3.1. 50) (Non-patent Document 20). Sphingomyelin is a major sphingolipid that exists outside the cell membrane.
  • lysosphingomyelin also known as sphingosyl phosphorylcholine (SPC)
  • SPC sphingosyl phosphorylcholine
  • Non-patent literature 5 In recent years, it has been reported that SPC is elevated in patients with acid sphingomyelinase deficiency as well as NPC patients, suggesting that plasma components may not affect the metabolism of SPC.
  • Non-Patent Document 21 In this study, selective accumulation of SPC in NPC can only be detected in plasma, not in dried filter paper samples, and SPC in red blood cells may not be affected by NPC-mediated metabolism. Have also been found (Non-Patent Document 21).
  • lysosphingomyelin-509 is known as a novel biomarker whose chemical property accumulated in the plasma of NPC patients has not been determined (Non-patent documents 21 and 23 and Patent documents 1 and 2) .
  • Polo et al. Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS / MS Clin Chem Lab Med 55 (2017) 403-414.
  • A. K. Giese et al. A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease, Orphanet J. Rare Dis. 10 (2015) 78. T.
  • Cholesterol oxidation products such as cholestane-3 ⁇ , 5 ⁇ , 6 ⁇ -triol and 7-ketocholesterol are to be used as target samples of the plasma to avoid the effects of artificial oxidation reactions that may occur before quantitative analysis
  • the supernatant should be centrifuged immediately after freezing, and the supernatant should be cryopreserved under cryogenic temperature and transported to the laboratory while being kept frozen.
  • preparation, storage and transport of such samples should be conducted according to a predetermined procedure, there is a problem in that cost and labor are generally required for arranging refrigerants such as dry ice and means for transporting in frozen state. There is.
  • refrigerants such as dry ice and means for transporting in frozen state.
  • an accident may occur during transportation of the sample, for example, a frozen sample may be melted because all the dry ice is vaporized.
  • cholestane-3 ⁇ , 5 ⁇ , 6 ⁇ -triol and 7-ketocholesterol are oxidation products of cholesterol, and therefore, in addition to the endogenous accumulation to be quantified as a biomarker, artificially generated oxidation products during analytical procedures When the accumulation amount of the substance is significantly large, there is a problem that the normal control sample also exhibits a high level as recognized in the disease group.
  • the concentrations of compounds present in the plasma such as cholestane-3 ⁇ , 5 ⁇ , 6 ⁇ -triol and 7-ketocholesterol, and SPC also fluctuate to some extent under physiological conditions due to metabolic reduction and concentration by perspiration.
  • compounds present in the plasma such as cholestane-3 ⁇ , 5 ⁇ , 6 ⁇ -triol and 7-ketocholesterol, and SPC also fluctuate to some extent under physiological conditions due to metabolic reduction and concentration by perspiration.
  • biomarkers even in the case of a plurality of biomarkers, all of them have been measured to a single sample. Therefore, if the measured biomarkers rise or fall uniformly, there is no means to correct this.
  • One aspect of the present invention aims to realize a test method that improves diagnostic accuracy for Niemann-Pick disease type C in the case of using a biomarker alone and in comparison with the conventional method described above.
  • a test method for diagnosis of Niemann-Pick disease type C comprises an amount of a first biomarker in a blood-derived sample collected from a living body And measuring the amount of the second biomarker in a sample derived from urine collected from the living body.
  • One embodiment of the present invention is also directed to an internal standard substance used for measuring the amount of the first biomarker in a blood-derived sample collected from a living body, and a sample derived from urine collected from the living body.
  • a test kit for diagnosis of Niemann-Pick disease type C or evaluation of the therapeutic effect of Niemann-Pick disease type C comprising an internal standard substance to be used in measuring the amount of the biomarker of No. 2 is provided.
  • diagnostic accuracy may be improved for Niemann-Pick disease type C, as compared to the single use of a biomarker and the conventional method described above.
  • A is D-erythro-sphingosyl phosphoryl choline (synthetic, SPC).
  • B is sphingosyl phosphoryl choline (C17 base, IS SPC ).
  • C is 3 ⁇ -sulfooxy-7 ⁇ -N-acetylglucosaminyl-5-coren-24-noic acid (SNAG- ⁇ 5 -CA).
  • D is 3 ⁇ -sulfooxy-7 ⁇ -hydroxy-23-nor-5- cholic acid (IS bile acid ). It is a figure which shows the calibration curve of IS SPC and SPC which used LC-MS / MS.
  • FIG. 7 shows selective accumulation of distinct SPCs in PBS (top) and plasma (bottom). Note that the amount of IS SPC was nearly constant during the assay.
  • FIG. 1 shows representative chromatograms for SPC and IS SPC from NPC patients and controls (healthy people).
  • FIG. 6 shows the elevation of plasma SPC and lysosphingomyelin-509 and urinary SNAG- ⁇ 5 -CA in NPC patients.
  • FIG. 5 shows the correlation of plasma and urine biomarker concentrations in NPC patients.
  • FIG. 5 shows the correlation of plasma and urine biomarker concentrations in NPC patients.
  • FIG. 6A shows the correlation between plasma SPC concentration and urinary bile acid metabolite SNAG- ⁇ 5 -CA concentration.
  • FIG. 6B shows the correlation between plasma lysosphingomyelin-509 concentration and urine SNAG- ⁇ 5 -CA concentration.
  • the concentration of SNAG- ⁇ 5 -CA was quantified using LC-MS / MS according to Non-Patent Document 11. 3 ⁇ -sulfooxy-7 ⁇ -hydroxy-23-nor-5-cholic acid was used as an internal standard.
  • An inspection method for diagnosis of Niemann-Pick disease type C is Measuring the amount of a first biomarker in a sample derived from blood collected from a living body (hereinafter referred to as "first step”); Measuring the amount of a second biomarker in a sample derived from urine collected from the living body (hereinafter referred to as “second step”); including.
  • first step may be performed before the second step, or the second step may be performed before the first step.
  • the first step and the second step may be performed in parallel.
  • biomarkers The first and second biomarkers and other biomarkers whose amounts can be measured in this embodiment are collectively referred to hereinafter simply as "biomarkers”.
  • examples of the living body include humans and animals other than humans (for example, mammals), and examples of mammals include mice, rats, rabbits, guinea pigs, primates excluding humans, and the like. Experimental animals; companion animals such as dogs and cats (pets); domestic animals such as cows, horses and pigs; humans.
  • the living body (subject) may be a newborn.
  • the inspection method according to the present embodiment may be performed as one of the items of the newborn screening test.
  • to measure the amount of biomarker is intended to measure the amount or concentration of the biomarker in a biological sample or a sample obtained by purifying the same.
  • the “amount of biomarker” may be an absolute amount (absolute mass or absolute concentration) or a relative amount (relative mass or relative concentration). In addition, for example, it may be a peak area in mass spectrometry, an emission intensity in luminescence measurement, or the like, or a value indicating how many times a predetermined standard is.
  • Niemann-Pick disease type C refers to having the etiology of Niemann-Pick disease type C, including when it has not yet developed typical clinical symptoms at this time It is a concept to gain.
  • the pathogenesis of Niemann-Pick disease type C includes genetic factors, and more specifically, a gene encoding NPC1 protein or NPC2 protein with reduced function (ie mutation of NPC1 gene or mutation of NPC2 gene) Include, but are not limited to, other known and unknown etiologies may also be included.
  • the "sample” used in the first step is a sample derived from blood collected from a living body (subject).
  • blood-derived samples include whole blood, serum, plasma and the like. Among the samples derived from blood, serum and plasma are preferable, and plasma is more preferable.
  • a blood collection site for example, a ovary fossa vein, a caudal cutaneous vein, and an ulnar cutaneous vein may be mentioned.
  • the first biomarker is the amount of the above-mentioned blood-derived sample (such as whole blood, serum, or plasma) in individuals having Niemann-Pick disease type C and individuals not suffering from Niemann-Pick disease type C It is a biomarker that has a statistically significant difference.
  • the first biomarker includes sphingophospholipids, cholestane-3 ⁇ , 5 ⁇ , 6 ⁇ -triol, 7-ketocholesterol, bile acid A and the like.
  • sphingophospholipids include sphingosyl phosphoryl choline (SPC), sphingosyl phosphoryl choline modified form, sphingomyelin, sphingomyelin modified form and the like.
  • the first biomarker is lysosphingomyelin-509.
  • the compound is compound 509 described in Patent Documents 1 and 2.
  • Lyso sphingomyelin -509 (Compound 509) is, C 24 H 50 O 7 N 2 P 509.3 having the empirical formula of the compound 509 (quasi-molecular M + H ions), more specifically 509.265 (m / z A substance having a pseudomolecular ion mass (as a monoisotopic pseudomolecular M + H ion).
  • a plasma sample derived from a subject from 509 m / z It may be a compound detected as MRM transition in ESI positive mode at 184 m / z (MRM transition).
  • the structural formula of compound 509 as [M + H] + is as follows, and preferably, the molecular weight of the compound of the following formula is 509.265 as monoisotopic pseudomolecular M + H ion (m / z).
  • Lysosphingomyelin-509 (compound 509) is also referred to as ⁇ -carboxy-sphingosyl phosphoryl choline.
  • the amount of the biomarker present can be quantitatively or semi-quantitatively
  • the method is not particularly limited as long as it can be determined, for example, mass spectrometry, a method using an immunological method using an antibody that recognizes a biomarker to be measured, a chemiluminescence method, an electrochemical detection method, ultraviolet light A detection method, a differential refraction method, or the like can be used.
  • Mass spectrometry may be performed using a known mass spectrometer. Mass spectrometry using a mass spectrometer is excellent in sensitivity and accuracy, so accurate determination can be performed. Furthermore, it is also possible to measure, for example, the amount of two or more biomarkers at once by using a multichannel mass spectrometer capable of multicomponent simultaneous analysis. Furthermore, biomarkers for other diseases than Niemann-Pick disease type C can also be measured at the same time, and detection of various diseases can be attempted at one time. Moreover, in order to perform detection more accurately, it is preferable to use a tandem mass spectrometer (MS / MS). The mass spectrometer used in the detection method of the present invention is not particularly limited as long as it can be quantified.
  • LC-MS liquid chromatography / mass spectrometry
  • Examples of methods using antibodies include ELISA, quantitative western blotting, radioimmunoassay, immunochromatography, and immunoprecipitation.
  • the type of ELISA method is not particularly limited, but is a so-called antigen measurement system (measurement of the amount of antigen contained in a biological sample), ELISA by direct adsorption method, ELISA by competition method, ELISA by sandwich method, and microflow An ELISA or the like specialized for measurement of a small amount of sample using a road type or microbeads can be mentioned.
  • the sample to be used for measurement of the amount of biomarker preferably contains an internal standard of known amount.
  • the amount of biomarker can be calculated more accurately.
  • variations between measurements can be suppressed, and diagnosis with high accuracy is possible.
  • data comparison among multiple facilities becomes easy.
  • by accumulating data at multiple facilities the accuracy of the reference value can be further improved.
  • analogues of biomarkers for example, isomers, homologues, compounds having different numbers of atoms in the main chain, compounds having different functional groups, or compounds whose chemical properties are similar to those of the biomarker and stable Compounds that can be quantified
  • stable isotope labeled compounds of biomarkers and the like.
  • the sample to be subjected to measurement of the amount of biomarker may be pretreated.
  • pretreatment include solvent extraction, solid phase extraction, HPLC (such as online HPLC), and derivatization.
  • solvent extraction method By performing pretreatment using a solvent extraction method, there is an advantage that the extraction operation including the compound to be measured can be easily achieved.
  • HPLC on-line HPLC or the like
  • Pretreatment using an HPLC (on-line HPLC or the like) method has an advantage that higher separation and purification with various kinds and precise fillers can be easily achieved as pretreatment.
  • turbidity fine particles
  • extract purified product
  • the sample may be filtered or centrifuged, for example, when fine particles are generated in the For example, it may be obtained from a blood plasma sample which is collected several hours after a particularly high lipid diet, a subject with suspected or confirmed dyslipidemia (eg familial hypercholesterolemia etc.) Samples and samples with high salt concentration or high protein concentration for some reason, etc. have a high possibility of generation of microparticles in the above (a) and (b).
  • SPC sphingosyl phosphoryl choline
  • blood is collected from a subject by a known method, and plasma is prepared by a known method.
  • an organic solvent containing an internal standard of known amount is added to plasma to make a sample solution.
  • Suitable internal standard substances for SPC include SPC-C17 (B in FIG. 1), SPC labeled with stable isotope, and the like.
  • the sample solution is applied to a solid phase extraction column. Elute the SPC and internal standard and dry under a stream of nitrogen. It is then resuspended in a solvent suitable for mass spectrometry and mass spectrometry is performed.
  • the concentration of SPC is calculated by comparing the peak area obtained with the peak area of the internal standard of known concentration.
  • sample used in the second step is a sample derived from urine collected from a living body (subject).
  • the living body (subject) in the first step and the living body (subject) in the second step are the same individual.
  • the second biomarker has a statistically significant difference in the amount of the above urine-derived sample between an individual suffering from Niemann-Pick disease type C and an individual not suffering from Niemann-Pick disease type C It is a biomarker.
  • the second biomarker includes bile acid metabolites and the like.
  • the bile acid metabolites, 3.beta .- Surufookishi -7 ⁇ -N- acetylglucosaminyltransferase-5-cholenic-24-Noikku acid (SNAG- ⁇ 5 -CA), 3 ⁇ - Surufookishi -7 ⁇ -N- acetylglucosaminyl - 5-cholenic-24-Noikku acid glycine conjugates (SNAG- ⁇ 5 -CG), 3 ⁇ - Surufookishi -7 ⁇ -N- acetylglucosaminyltransferase-5-cholenic-24-Noikku acid taurine conjugate (SNAG- ⁇ 5 - CT) etc.
  • the first biomarker and the second biomarker may be different from each other.
  • SNAG- ⁇ 5 -CA An example of a more specific method of the second step is described using SNAG- ⁇ 5 -CA as an example (see also the examples described later).
  • urine is collected from a subject by a known method.
  • an aqueous solution containing a known amount of internal standard substance is added to the urine to make a sample solution.
  • Preferred internal standards for SNAG- ⁇ 5 -CA include 3 ⁇ -sulfooxy-7 ⁇ -hydroxy-23-nor-5-cholic acid (D in FIG. 1) or stable isotope labeled SNAG- ⁇ 5- CA etc. are mentioned.
  • the sample solution is injected into a pre-equilibrated trapping column, washed with a solvent and eluted. Then, mass spectrometry is performed.
  • the concentration of SNAG- ⁇ 5 -CA is calculated by comparing the peak area obtained with the peak area of the internal standard of known concentration.
  • the amount of the first biomarker in the sample from the subject measured in the first step, and the amount of the second biomarker in the sample from the subject measured in the second step Based on, Niemann-Pick disease type C is determined.
  • the test method according to the present embodiment may include the step of comparing the amount of the first biomarker in the sample derived from the subject with the reference value of the first biomarker.
  • the inspection method according to the present embodiment may include the step of comparing the amount of the second biomarker in the sample derived from the subject with the reference value of the second biomarker.
  • data may be provided regarding the amount of the first biomarker in a sample derived from blood collected from a control subject.
  • data may be provided regarding the amount of the second biomarker in a sample derived from urine collected from a control subject.
  • the data may be measured in advance, or may be measured during a series of operations of the inspection method according to the present embodiment.
  • the control subject may be only an individual not suffering from Niemann-Pick disease type C, or only an individual suffering from Niemann-Pick disease type C, or both of them.
  • a control subject may be one individual, it is preferable that there are two or more individuals, and the more the number, the more preferable because the accuracy is improved.
  • a reference value derived from such data may be prepared.
  • the reference value takes into account statistical variation in, for example, the lower limit value in a control subject consisting of an individual suffering from Niemann-Pick disease type C, and the average value of a control subject consisting of an individual not suffering from Niemann-Pick disease type C These values, values in the literature, or any of these may be considered in combination.
  • Whether the subject suffers from Niemann-Pick disease type C if at least one of the amount of the first biomarker and the amount of the second biomarker in the sample derived from the subject is greater than or equal to the reference value in the biomarker It can be determined that the patient is likely to suffer from Niemann-Pick disease type C.
  • the amount of the first biomarker and the amount of the second biomarker are two-dimensionally plotted, and at least one of them is a reference value or more, you are suffering from Niemann-Pick disease type C, or Niemann-Pick disease type C It can be determined that there is a high possibility of suffering from Alternatively, the subject suffers from Niemann-Pick disease type C if both the amount of the first biomarker and the amount of the second biomarker in the sample from the subject are greater than or equal to the reference value in the biomarker. It can be determined that there is a high possibility of having or suffering from Niemann-Pick disease type C.
  • the amount of the biomarker in the sample derived from the subject is compared with a reference value, and the difference is determined by, for example, a statistical method such as t test, F test, chi-square test, or Mann-Whitney's U test.
  • the probability of suffering from Niemann-Pick disease type C may be calculated according to
  • the amount of the first biomarker and the amount of the second biomarker may be converted into one parameter (value) and used.
  • the amount of the first biomarker and the amount of the second biomarker are used to calculate a logistic regression score.
  • the calculation method may be, for example, the method described in the literature: Pepe, MS, Cai, T., and Longton, G. (2006), Biometrics 62, 221-229.
  • the reference value can also be calculated as one parameter (value) in the same manner. For this logistic regression score, if the subject is higher than the standard value, determine that the subject is likely to suffer from Niemann-Pick disease type C or is likely to suffer from Niemann-Pick disease type C. Can.
  • the logistic regression score in the sample derived from the subject is compared with the reference value, and the significant difference thereof is determined by a statistical method such as t test, F test, chi-square test, or Mann-Whitney's U test.
  • the probability of suffering from Niemann-Pick disease type C may be calculated.
  • test method according to the present embodiment utilizes two biomarkers respectively derived from different samples from the same subject, diagnostic accuracy is improved when using one biomarker alone and in comparison with the conventional method. Can improve.
  • One embodiment of the present invention is based on the amount of the first biomarker and the amount of the second biomarker in the sample from the subject measured in the above-mentioned test method, and the subject suffers from Niemann-Pick disease type C.
  • the present invention provides a diagnostic method for Niemann-Pick disease type C, which includes the step of determining whether or not the patient is likely to suffer from Niemann-Pick disease type C.
  • a diagnostic method for Niemann-Pick disease type C which includes the step of determining whether or not the patient is likely to suffer from Niemann-Pick disease type C.
  • when at least one of the amount of the first biomarker and the amount of the second biomarker in the sample derived from the subject measured in the above test method is equal to or greater than a reference value in the biomarker, It is determined that the subject has Niemann-Pick disease type C or is likely to suffer from Niemann-Pick disease type C.
  • both the amount of the first biomarker and the amount of the second biomarker in the sample derived from the subject measured in the above-mentioned test method are equal to or higher than the reference value in the biomarker, Determining that the body suffers from Niemann-Pick disease type C or is likely to suffer from Niemann-Pick disease type C.
  • the test method according to the present embodiment may include the step of measuring the amount of additional biomarkers other than the first biomarker and the second biomarker.
  • test method according to the present embodiment includes “a step of measuring the amount of the first biomarker in the sample derived from blood and the amount of the second biomarker in the sample derived from urine. It can also be referred to as “test method for diagnosis of disease type C”.
  • test method according to the present embodiment includes “a step of testing using a first biomarker in a sample derived from blood and a second biomarker in a sample derived from urine. It can also be referred to as “test method for diagnosis of type”.
  • the present invention further provides a test method for evaluating the therapeutic effect of Niemann-Pick disease type C, which comprises the above-mentioned first step and the above-mentioned second step.
  • the test method includes the amount of the first biomarker in the sample from the subject at the first time point and the amount of the first biomarker in the sample from the subject at the second time point A step of comparing may be included.
  • the amount of the second biomarker in the sample derived from the subject at the first time point and the amount of the second biomarker in the sample derived from the subject at the second time point A step of comparing may be included.
  • the first time point may be at some time before or after the start of treatment for Niemann-Pick disease type C (including after the end of treatment).
  • the second time point may be later than the first time point and at a certain time point after the start of the treatment (including after the end of the treatment).
  • the amount of biomarker in the sample from the subject at the second time point is reduced compared to the amount of biomarker in the sample from the subject at the first time point, then there is a therapeutic effect It can be evaluated.
  • the amount of biomarker in the sample from the subject at the second time point is reduced compared to the amount of biomarker in the sample from the subject at the first time point, then there is a therapeutic effect It can be evaluated.
  • the first biomarker or the second biomarker may be evaluated as having a therapeutic effect, or only if both have a therapeutic effect. May be Alternatively, the amount of the first biomarker and the amount of the second biomarker may be converted into one parameter (value) and compared as described above.
  • the test method according to the present embodiment may include the step of measuring the amount of additional biomarkers other than the first biomarker and the second biomarker.
  • test method according to the present embodiment includes “a step of measuring the amount of the first biomarker in the sample derived from blood and the amount of the second biomarker in the sample derived from urine. It can also be referred to as “test method for evaluating the treatment effect of disease type C”.
  • test method according to the present embodiment includes “a step of testing using a first biomarker in a sample derived from blood and a second biomarker in a sample derived from urine. It can also be referred to as “test method for evaluating the therapeutic effect of type”.
  • Test methods for evaluating the therapeutic effect of Niemann-Pick disease type C may be used for screening of therapeutic agents. That is, a candidate compound of a therapeutic agent can be administered to a subject, evaluation of the therapeutic effect of Niemann-Pick disease type C can be performed as described above, and it can be determined that a candidate compound having a therapeutic effect can be used as a therapeutic agent. .
  • the present invention further provides a test kit for diagnosing Niemann-Pick disease type C or for evaluating the therapeutic effect of Niemann-Pick disease type C.
  • the said test kit can be suitably used for implementation of the test method for a diagnosis of Niemann-Pick disease type C mentioned above, or the test method for evaluation of the therapeutic effect of Niemann-Pick disease type C.
  • the test kit includes an internal standard substance used when measuring the amount of the first biomarker in a sample derived from blood collected from a living body, and a sample derived from urine collected from the living body And an internal standard used to measure the amount of the second biomarker.
  • the internal standard is described above [1. Test method for diagnosis of Niemann-Pick disease type C] is as described in the section.
  • the internal standard may be included in the form of a solution, in the form of a solid, etc.
  • the test kit according to the present embodiment further includes a solid phase extraction tube, a solid phase extraction plate, a dilution liquid, a washing liquid, an elution liquid, and a container for the first biomarker.
  • the test kit according to the present embodiment may include any combination of these.
  • the test kit may include either a solid phase extraction tube or a solid phase extraction plate.
  • the test kit may include a diluent, a washing solution and an eluent in combination.
  • the test kit may be a kit suitable for pretreatment by solid phase extraction.
  • the solid phase extraction tube is a solid phase extraction tube for purifying a biomarker.
  • a solid phase extraction tube a syringe type solid phase extraction tube is mentioned, for example.
  • the solid phase extraction tube is more suitable when the number of samples to be processed at one time is relatively small (for example, but not limited to, about 1 to 20).
  • the solid phase extraction plate is a solid phase extraction plate for purifying a biomarker.
  • a solid phase extraction plate in 96 well format can be mentioned.
  • the solid phase extraction plate is more suitable when the number of samples to be processed at one time is relatively large (but not limited to, for example, 20).
  • the diluent is, for example, a liquid for diluting a sample containing a biomarker.
  • the diluent used to dilute the blood-derived sample may be appropriately selected by those skilled in the art depending on the type of biomarker, but it may be, for example, water, a solid phase containing an organic solvent to sufficiently dissolve the biomarker, and conditioned. Examples include an aqueous solution in which the biomarker is sufficiently retained on the solid phase when added to an extraction tube, and Solution 1 (75% water + 25% methanol + 0.1% H 3 PO 4 ) described later.
  • the diluent used to dilute the urine-derived sample may be appropriately selected by those skilled in the art depending on the type of biomarker, but it may be, for example, water, a solid phase containing an organic solvent to sufficiently dissolve the biomarker and conditioned.
  • the washing solution is, for example, a liquid for washing the solid phase extraction tube or the solid phase extraction plate in which the biomarker is held.
  • a liquid for washing the solid phase extraction tube or the solid phase extraction plate in which the biomarker is held.
  • Such a liquid can be appropriately selected by those skilled in the art depending on the type of biomarker, and examples include Solution 1 and Solution 2 described in the examples below.
  • the washing solution may be contained in the kit may be one type or two or more types.
  • the eluate is, for example, a liquid for eluting the biomarker from the solid phase extraction tube or the solid phase extraction plate in which the biomarker is retained.
  • a liquid for eluting the biomarker from the solid phase extraction tube or the solid phase extraction plate in which the biomarker is retained.
  • Such a liquid can be appropriately selected by those skilled in the art depending on the type of biomarker, and examples thereof include Solution 3 described in the examples below.
  • the container is, for example, a container for mixing the sample containing the biomarker and the internal standard substance, or a container for collecting the eluate containing the biomarker and the internal standard substance.
  • the container is, for example, a tube or a plate.
  • the volume of the container may be, for example, about 1.5 mL to 2.0 mL. Examples of the material of the container include plastic, glass and the like.
  • Test method for diagnosis of Niemann-Pick disease type C The contents of the test method for diagnosis of Niemann-Pick disease type C according to the present invention described in the section of the present invention, and / or the above [2. Test Method for Evaluating Therapeutic Effect of Niemann-Pick Disease Type C According to the Present Invention Described in the section of 2. The contents of the examination method for evaluating the treatment effect of Niemann-Pick disease type C are recorded.
  • the test kit according to the present embodiment is a control sample used in measurement, a first biomarker in a sample derived from blood collected from a control subject used when analyzing measurement results.
  • Data on the amount, data on the amount of the second biomarker in the sample derived from urine collected from the control subject used when analyzing the measurement results, a reference value derived from at least one of these data (The reference value for the first biomarker, the reference value for the second biomarker, and / or the amount of the first biomarker and the amount of the second biomarker are converted into one parameter (value)
  • a medium in which at least one of the data of the reference value of the case, etc.) is described or recorded may be included.
  • test kit according to the present embodiment can be used, for example, in combination with any one or more of the following. These may be prepared by the user. Alternatively, in another embodiment, any one or more of these may be included as a component of the test kit.
  • Vials for autosamplers etc. eg (a) vials made of glass or plastic compatible with LC-MS autosampler sample table used and vial caps with Teflon (R) seal, or (b) deep bottom 96 Well plate and organic solvent resistant dedicated seal for LC-MS analysis for the purpose of preventing solvent evaporation, dedicated mat for preventing solvent evaporation, or aluminum foil etc.
  • Equipment for solvent removal for example, (a) a dedicated instrument for solvent removal which has a nitrogen generator, nitrogen cylinder, etc., and a head compatible with 1.5 mL tubes and 96 wells, (b) centrifugal Concentrator, etc.), Solid phase extraction apparatus (for example, pressure type of syringe type, pressure reduction type using vacuum pump or water flow pump, etc.), Devices used for sample filtration or centrifugation (for both filtration and centrifugation, single (directly connected to a syringe)) and devices corresponding to 96 wells, etc.
  • Equipment for solvent removal for example
  • Centrifugal filter tubes The column may be packed with a solid phase extraction carrier, and may be in the form of solid phase extraction by centrifugation using a tube).
  • Analytical columns required for LC-MS, mobile phase solvents, etc. water, organic solvents, and additives such as ionizing agents), In addition, reagents (methanol for LC-MS, acetonitrile, MilliQ water, etc.) and equipment generally used for LC-MS as needed.
  • the invention further provides a test system for measuring the amount of the first biomarker and the amount of the second biomarker.
  • the test system may include, as a component, software (a program) for measuring the amount of the first biomarker and / or the amount of the second biomarker.
  • the program may be stored in a computer-readable recording medium, and as such a recording medium, "non-temporary tangible medium", for example, ROM (Read Only Memory), etc. Examples include tapes, disks, cards, semiconductor memories, and programmable logic circuits.
  • the program may be supplied to the computer via any transmission medium (communication network, broadcast wave, etc.) capable of transmitting the program.
  • Test Method for Diagnosis of Niemann-Pick Disease Type C The result obtained by performing the test method described in the section can be used as one of diagnostic data when a doctor makes a diagnosis. Moreover, the above [1. Test method for diagnosis of Niemann-Pick disease type C]] By performing the test method described in the section, there is a need for a subject for which the result that there is a possibility of suffering from Niemann-Pick disease type C is obtained Depending on the result of the definite diagnosis by the doctor, the treatment can be performed. In particular, in the examination method according to the present embodiment, since Niemann-Pick disease type C can be detected with high accuracy, early diagnosis and early treatment can be realized.
  • a definite diagnosis can be performed in consideration of family history and the like. Based on this, a treatment plan is made.
  • a test method for diagnosis of Niemann-Pick disease type C comprises an amount of a first biomarker in a blood-derived sample collected from a living body And measuring the amount of the second biomarker in a sample derived from urine collected from the living body.
  • the first biomarker is preferably a sphingophospholipid.
  • the sphingophospholipid is more preferably sphingosyl phosphoryl choline.
  • the sphingophospholipid is more preferably lysosphingomyelin-509.
  • the second biomarker is preferably a bile acid metabolite.
  • the bile acid metabolite is 3 ⁇ -sulfoxy-7 ⁇ -N-acetylglucosaminyl-5-colene-24-noic acid (SNAG- ⁇ 5 -CA) Is more preferred.
  • test method it is preferable to use an internal standard substance in measurement of the amount of the first biomarker.
  • test method it is preferable to use an internal standard substance in measurement of the amount of the second biomarker.
  • the test method it is preferable to measure the amount of the first biomarker and the amount of the second biomarker by LC-MS.
  • One embodiment of the present invention is also directed to an internal standard substance used for measuring the amount of the first biomarker in a blood-derived sample collected from a living body, and a sample derived from urine collected from the living body.
  • a test kit for diagnosis of Niemann-Pick disease type C or evaluation of the therapeutic effect of Niemann-Pick disease type C comprising an internal standard substance to be used in measuring the amount of the biomarker of No. 2 is provided.
  • D-erythro-sphingosyl phosphoryl choline (synthetic SPC) was purchased from Toronto Research Chemicals.
  • Deionized water was obtained from Milli-Q water system (Millipore).
  • Ammonium acetate and formic acid were purchased from Kanto Chemical Co., Ltd.
  • the Oasis HLB 96-well plate was purchased from Waters.
  • 3 ⁇ -sulfooxy-7 ⁇ -hydroxy-23-nor-5-cholenic acid was synthesized as described in 11 and 24 and was used as an internal standard substance (IS bile acid ) for SNAG- ⁇ 5- CA Using.
  • the other reagents used in this study were the highest grade commercially available.
  • the chemical structures of the compounds used in this study are shown in FIG.
  • the mean rise in plasma SPC concentration in NPC patients was 2.6 times that of controls (Table 9).
  • FIG. 6A shows a summary of the correlation between plasma SPC and urinary bile acid metabolite SNAG- ⁇ 5 -CA.
  • all NPC patients evaluated in this study showed higher concentrations in either SPC or SNAG- ⁇ 5 -CA.
  • the present invention can be used for a clinical test kit for diagnosis of Niemann-Pick disease type C, an analysis method package including software, and the like.

Abstract

L'invention concerne un procédé de test qui a une précision améliorée de diagnostic de la maladie de Niemann-Pick de type C par rapport à celle pour l'utilisation d'un biomarqueur unique et celle pour des procédés classiques, le procédé de test pour le diagnostic du type de la maladie de Niemann-Pick de type C comprenant : une étape de mesure de la quantité d'un premier biomarqueur dans un échantillon provenant de sang prélevé à partir d'un corps vivant et une étape de mesure de la quantité d'un second biomarqueur dans un échantillon provenant d'urine recueillie à partir du corps vivant.
PCT/JP2018/046159 2017-12-18 2018-12-14 Procédé de test pour le diagnostic de la maladie de niemann-pick type c WO2019124267A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017242131A JP2021036201A (ja) 2017-12-18 2017-12-18 ニーマンピック病ｃ型の診断のための検査方法
JP2017-242131 2017-12-18

Publications (1)

Publication Number Publication Date
WO2019124267A1 true WO2019124267A1 (fr) 2019-06-27

Family

ID=66992972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/046159 WO2019124267A1 (fr) 2017-12-18 2018-12-14 Procédé de test pour le diagnostic de la maladie de niemann-pick type c

Country Status (2)

Country Link
JP (1) JP2021036201A (fr)
WO (1) WO2019124267A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521694A (ja) * 2007-03-21 2010-06-24 バイオポルト・ダイアグノスティクス・アクティーゼルスカブ 腎傷害のための診断テスト
WO2011136228A1 (fr) * 2010-04-27 2011-11-03 シスメックス株式会社 Marqueur de diagnostic pour maladies rénales et son utilisation
WO2016078762A1 (fr) * 2014-11-19 2016-05-26 Centogene Ag Méthode pour diagnostiquer la maladie de niemann-pick à l'aide d'un biomarqueur

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521694A (ja) * 2007-03-21 2010-06-24 バイオポルト・ダイアグノスティクス・アクティーゼルスカブ 腎傷害のための診断テスト
WO2011136228A1 (fr) * 2010-04-27 2011-11-03 シスメックス株式会社 Marqueur de diagnostic pour maladies rénales et son utilisation
WO2016078762A1 (fr) * 2014-11-19 2016-05-26 Centogene Ag Méthode pour diagnostiquer la maladie de niemann-pick à l'aide d'un biomarqueur

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAEKAWA MASAMITSU ET AL.: "LC/ESI-MS/MS analysis of urinary 3 beta -sulfooxy-7 beta -N-acetylglucosaminyl-5-cholen-24-oic acid and its amides: New biomarkers for the detection of Niemann-Pick type C disease", STEROIDS, vol. 78, 2013, pages 967 - 972, XP055135046, doi:10.1016/j.steroids.2013.05.017 *
MASHIMA RYUITI ET AL.: "Elevation of plasma lysosphingomyelin-509 and urinary bile acid metabolite in Niemann-Pick disease type C-affected individuals", MOLECULAR GENETICS AND METABOLISM REPORTS, vol. 15, 10 March 2018 (2018-03-10), pages 90 - 95, XP055620061, ISSN: 2214-4269, DOI: 10.1016/j.ymgmr.2018.03.005 *

Also Published As

Publication number Publication date
JP2021036201A (ja) 2021-03-04

Similar Documents

Publication Publication Date Title
Lista et al. Blood and plasma-based proteomic biomarker research in Alzheimer's disease
Adaway et al. Liquid chromatography tandem mass spectrometry in the clinical laboratory
Möller et al. Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing
EP3511973B1 (fr) Quantification de l'insuline par spectrométrie de masse
JP2018511812A (ja) 質量分析によるインスリンレベルの定量の方法
Beasley-Green Urine proteomics in the era of mass spectrometry
US10983108B2 (en) Methods for quantitation of insulin and C-peptide
Gilquin et al. Multiplex and accurate quantification of acute kidney injury biomarker candidates in urine using Protein Standard Absolute Quantification (PSAQ) and targeted proteomics
Iadarola et al. Recent applications of CE‐and HPLC‐MS in the analysis of human fluids
Chen et al. Elevated levels of oxidative nucleic acid modification markers in urine from gastric cancer patients: quantitative analysis by ultra performance liquid chromatography-tandem mass spectrometry
EP2480895A1 (fr) Méthode diagnostique de la stéatose hépatique non alcoolique basée sur le profil métabolique
US20210048445A1 (en) Methods and Systems for Measuring Serotonin in a Sample
WO2018231415A1 (fr) Procédés d'extraction et de mesure de concentrations de biomolécules dans des matrices complexes sans nécessiter une immunocapture
US20150011423A1 (en) Means and methods for assessing kidney toxicity
Sidhu et al. A HILIC‐MS/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum
Chen et al. Targeted protein quantitation in human body fluids by mass spectrometry
Nauwelaerts et al. Development of a multiplex mass spectrometry method for simultaneous quantification of urinary proteins related to respiratory health
Lassman et al. The clinical utility of mass spectrometry based protein assays
Rezeli et al. MRM assay for quantitation of complement components in human blood plasma—a feasibility study on multiple sclerosis
Bąchor et al. Identyfication of tryptic podocin peptide in the feline urine sediments using LC-MS/MRM method
EP2932274A1 (fr) Procédé pour le diagnostic de la leucodystrophie métachromatique
US11929243B2 (en) Apolipoprotein E isotype detection by mass spectrometry
Gu et al. Simultaneous quantification of GM1 and GM2 gangliosides by isotope dilution tandem mass spectrometry
WO2019124267A1 (fr) Procédé de test pour le diagnostic de la maladie de niemann-pick type c
Maes et al. Introducing plasma/serum glycodepletion for the targeted proteomics analysis of cytolysis biomarkers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18890133

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18890133

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP